Drug Search Results
More Filters [+]

SB-756050

Alternative Names: sb-756050, sb756050, sb 756050
Latest Update: 2017-09-06
Latest Update Note: Clinical Trial Update

Product Description

a selective TGR5 agonist, SB-756050, for patients with T2D (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27121782/)

Mechanisms of Action: TGR5 Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SB-756050

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT00733577

P1

Completed

Type 2 Diabetes

2009-03-03

AXO110461

P1

Completed

Type 2 Diabetes

2008-03-10

Recent News Events

Date

Type

Title